Xu Yongjie, Xia Changfa, Wang Jiachen, Wu Yujie, Chen Wanqing
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Natl Cancer Cent. 2025 May 29;5(3):306-312. doi: 10.1016/j.jncc.2025.05.001. eCollection 2025 Jun.
While China's socioeconomic transformation has driven divergent trends in gastrointestinal cancers, comprehensive data on esophageal, gastric, and liver cancer burden remain limited. This study examines the global burden of esophageal, gastric, and liver cancers in 2022 and analyzes the trends of age-standardized incidence and mortality rate (ASRs) in China from 2000 to 2018, thereby providing evidence for the formulation of cancer control strategies.
The global burden of esophageal, gastric and liver cancers including the estimated number of cases and deaths and the ASRs for incidence and mortality were from GLOBALCAN 2022 dataset. Data from 22 cancer registries in China were employed for the trend analysis of the ASRs for incidence and mortality of these three cancers. The Joinpoint model was used to compute the average annual percentage change (AAPC) of the incidence and mortality of the three cancers from 2000 to 2018.
Globally, esophageal, gastric and liver cancers accounted for 11.8 % of incident cancer cases and 19.1 % of cancer deaths. China bore a disproportionately high burden, representing 43.8 %, 37.0 %, and 42.4 % of global esophageal, gastric, and liver cancer cases respectively, and 42.1 %, 39.4 %, and 41.7 % of corresponding deaths. However, the ASRs for incidence and mortality for all three cancers declined significantly in China (2000-2018), with absolute case numbers decreasing for gastric and esophageal cancers during 2010-2022. Age-specific analysis revealed most pronounced declines in incidence and mortality in populations under 40 years old, with AAPCs of less than -6.0 % for esophageal cancer, around -4.0 % for gastric cancer, and approximately -2.0 % for liver cancer.
China has achieved remarkable progress in controlling esophageal, gastric and liver cancers, yet these malignancies remain major public health challenges. Future efforts should intensify existing prevention measures while expanding screening programs, particularly for aging populations. These findings offer valuable insights for regions undergoing similar epidemiological transitions.
虽然中国的社会经济转型导致了胃肠道癌症的不同发展趋势,但关于食管癌、胃癌和肝癌负担的全面数据仍然有限。本研究调查了2022年食管癌、胃癌和肝癌的全球负担,并分析了2000年至2018年中国年龄标准化发病率和死亡率(ASRs)的趋势,从而为制定癌症控制策略提供依据。
食管癌、胃癌和肝癌的全球负担,包括估计的病例数和死亡数以及发病率和死亡率的年龄标准化率,来自GLOBALCAN 2022数据集。中国22个癌症登记处的数据用于这三种癌症发病率和死亡率年龄标准化率的趋势分析。Joinpoint模型用于计算2000年至2018年这三种癌症发病率和死亡率的年均变化百分比(AAPC)。
在全球范围内,食管癌、胃癌和肝癌占新发癌症病例的11.8%,占癌症死亡的19.1%。中国负担过高,分别占全球食管癌、胃癌和肝癌病例的43.8%、37.0%和42.4%,以及相应死亡的42.1%、39.4%和41.7%。然而,中国这三种癌症的发病率和死亡率年龄标准化率在2000 - 2018年期间显著下降,2010 - 2022年期间胃癌和食管癌的绝对病例数减少。按年龄分析显示,40岁以下人群的发病率和死亡率下降最为明显,食管癌的年均变化百分比小于 - 6.0%,胃癌约为 - 4.0%,肝癌约为 - 2.0%。
中国在控制食管癌、胃癌和肝癌方面取得了显著进展,但这些恶性肿瘤仍然是重大的公共卫生挑战。未来的努力应加强现有的预防措施,同时扩大筛查项目,特别是针对老年人群。这些发现为经历类似流行病学转变的地区提供了有价值的见解。